Novartis AG ADR (NVS)vsZimmer Biomet Holdings Inc (ZBH)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
ZBH
Zimmer Biomet Holdings Inc
$82.43
+2.95%
HEALTHCARE · Cap: $15.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 573% more annual revenue ($56.58B vs $8.41B). NVS leads profitability with a 23.9% profit margin vs 9.1%. ZBH appears more attractively valued with a PEG of 0.55. ZBH earns a higher WallStSmart Score of 71/100 (B).
NVS
Buy51
out of 100
Grade: C-
ZBH
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+35.9%
Fair Value
$149.15
Current Price
$82.43
$66.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Growing faster than its price suggests
Earnings expanding 34.1% YoY
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
ROE of 6.1% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : ZBH
The strongest argument for ZBH centers on Price/Book, PEG Ratio, EPS Growth. PEG of 0.55 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : ZBH
The primary concerns for ZBH are Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a declining stock while ZBH is a value play — different risk/reward profiles.
ZBH carries more volatility with a beta of 0.61 — expect wider price swings.
ZBH is growing revenue faster at 9.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ZBH scores higher overall (71/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Zimmer Biomet Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?